What Vasopressin is
Vasopressin is an endogenous peptide hormone involved in vascular tone and water-balance signaling through vasopressin receptors.
Vasopressin is grouped under Endogenous / Biology / Approved / Clinical on PeptideFactCheck because it is a foundational peptide hormone and helps distinguish physiology from optimization claims.
The useful starting point is to separate the molecule itself from the internet story around it. It is often paired conceptually with oxytocin as a neuroendocrine peptide.
Why people keep looking it up
People associate vasopressin with water balance, blood pressure, and stress physiology.
Vasopressin signals through receptors involved in water retention and vascular tone.
Vasopressin tends to stay in the conversation because it touches a familiar public theme: v1 receptor, v2 receptor, and water balance. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
It is clinically meaningful biology, not casual optimization territory.
Human physiology and official drug labels support specific clinical contexts.
Mechanistic biology is well characterized across receptor subtypes.
Why this page carries the current tier: Endogenous hormone with approved drug products and mature physiology.
The current seed trail for Vasopressin is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Clinical context is critical because water balance and vascular effects can be consequential.
FDA-approved vasopressin products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Vasopressin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Vasopressin is CID 644077. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 644077
- Formula
- C46H65N15O12S2
- Molecular weight
- 1084.2
- InChIKey
- KBZOIRJILGZLEJ-LGYYRGKSSA-N
Matched synonyms include ARGIPRESSIN, 113-79-1, Argipressine, Arginine vasopressin, Vasopressin injection, Argipresina, Argipressina, Argipressinum.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Vasopressin returns 418 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Vasopressin returns 54544 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- VASOPRESSIN
- Generic names
- VASOPRESSIN
- Routes
- INTRAVENOUS
- Application numbers
- ANDA213206
Indications and usage. 1 INDICATIONS AND USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. • Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS • Can worsen cardiac function. ( 5.1 ) • Reversible diabetes insipidus ( 5.2 ) 5.1 Worsening Cardiac Function A decrease in cardiac index may be observed with the use of vasopressin. 5.2 Reversible Diabetes Insipidus Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopres...
Contraindications. 4 CONTRAINDICATIONS Vasopressin injection 1 mL single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin. • Vasopressin injection 1 mL single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin. ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.